Wegovy Cost Calculator 2026 — Insurance, NovoCare $499 Vials, and Cash Paths

Wegovy Cost in 2026: What You Actually Pay Depends on Your Path

Novo Nordisk's list price for Wegovy in 2026 is $1,349 per 28-day supply — the same price across all dose strengths. But almost nobody pays list. The real number you pay depends entirely on which of four access paths your situation supports: insurance with a copay, the Novo savings card, NovoCare's direct-pay vial program, or compounded semaglutide (now restricted post-FDA shortage delisting).

Use the calculator above to model your specific scenario. Select your access path, enter your actual copay or program price, and set the number of months you want to budget for. The results show your monthly cost and total outlay for the period — without any marketing spin about what Wegovy "could" cost.

The path that matters most: if your commercial plan covers Wegovy, the Novo Nordisk savings card can bring your covered copay to as low as $0/month (maximum benefit $225 off per 28-day supply, $3,500 annual cap). That is the best-case scenario and applies to a narrower population than Novo's marketing implies — only commercially insured patients whose plans cover Wegovy.

How to Use This Calculator

Start by selecting your access path from the dropdown. If you have insurance and your plan covers Wegovy, select "Insurance with copay" and enter your actual copay from your Explanation of Benefits or your pharmacy benefit manager's cost estimator tool. If you're uninsured or your plan excludes anti-obesity medications, select the NovoCare vials option ($499/month, maintenance doses only) or the savings card cash-pay path (~$500/month).

The compounded semaglutide option is included for completeness, but note the regulatory context: the FDA removed semaglutide from the drug shortage list in late 2024, ending the broad 503A compounding pathway for general weight loss use. Platforms still selling $199–$349/month compounded semaglutide widely in 2026 warrant scrutiny — verify your pharmacy's legal basis for compounding before purchasing.

Enter the number of months you're planning for. Wegovy is designed as long-term maintenance therapy — STEP-4 withdrawal data showed approximately two-thirds of lost weight returned within 12 months of stopping. Budget accordingly: a 12-month horizon is useful for annual planning, but a 36- or 60-month projection gives a truer picture of the actual financial commitment.

The Four Wegovy Access Paths Explained

Understanding the mechanics of each path prevents expensive mistakes:

Path 1 — Insurance with Novo savings card: Commercial plans that cover anti-obesity medications (roughly 35–45% of large-employer plans as of 2026, per Kaiser Family Foundation tracking) typically require prior authorization with BMI 30+ or BMI 27+ with at least one weight-related comorbidity. With a covered plan, the Novo Nordisk savings card brings your copay to $0/month for fills where the copay would otherwise exceed $225, up to a $3,500 annual cap. For a $250 specialty-tier copay, that's essentially free Wegovy for the first ~14 fills of the year, then $250/month after the cap is reached. Best financial outcome if you qualify.

Path 2 — Novo savings card, cash-pay: If your plan doesn't cover Wegovy (or you're uninsured), the same savings card applied to a retail prescription gives a maximum of $500/month off list price, landing you at approximately $849–$999/month depending on pharmacy. NovoCare vials are usually a better deal — but vials only cover maintenance doses.

Path 3 — NovoCare self-pay vials ($499/month): Launched by Novo Nordisk in late 2025 as a direct response to Eli Lilly's LillyDirect Zepbound vial program. Available for 1.7 mg and 2.4 mg doses only — the two highest maintenance strengths. Starter doses (0.25 mg, 0.5 mg, 1 mg, 1.7 mg in the titration context) are not available as NovoCare vials; you'll need branded pens from a retail pharmacy during the titration phase. NovoCare is cash-pay only — dollars spent don't count toward your health plan deductible or out-of-pocket maximum. HSA and FSA funds are eligible.

Path 4 — Compounded semaglutide: The FDA removed semaglutide from the drug shortage list in late 2024. That ended the broad compounding exemption that had allowed pharmacies to legally compound semaglutide for general weight loss without a patient-specific medical necessity basis. Legitimate compounded semaglutide in 2026 requires documented individual need (typically an allergy to a branded inactive ingredient). If a platform is offering you $199/month compounded semaglutide without that individualized basis, verify their compliance posture before purchasing.

Real Example: Budgeting Wegovy as a Self-Pay Patient at Maintenance Dose

Consider a 38-year-old woman already at her Wegovy maintenance dose of 2.4 mg, uninsured, with no AOM coverage. She was previously paying $1,349/month at a retail pharmacy and has just learned about NovoCare.

Before NovoCare: $1,349 × 12 = $16,188/year at pharmacy list price.
After switching to NovoCare vials: $499 × 12 = $5,988/year. Annual savings: $10,200.
Using FSA ($3,050/year, 2026 limit): Pre-tax dollars cover 6.1 months of NovoCare. Net taxable out-of-pocket drops to $2,938, saving an additional ~$732 at the 24% bracket.

The practical adjustment for her: NovoCare ships multi-dose vials requiring self-administration with a syringe. She was using the Wegovy autoinjector pen. The switch takes one or two practice draws — Novo provides injection guides. The difference is delivery format, not drug formulation.

Five-year NovoCare budget at 2.4 mg maintenance: $499 × 60 = $29,940. That is the honest long-term number — and it's why pursuing insurance coverage through employer benefits negotiations or prior authorization appeals remains worth the effort. A single covered plan saves $24,000 over five years versus NovoCare at the same dose.

Wegovy vs. Zepbound: The 2026 Cost and Efficacy Comparison

Patients frequently ask which drug is cheaper. The honest answer depends on which path you're on:

• With insurance coverage: Both land at roughly $0–$50/month with their respective savings cards. Cost is essentially equal — choose based on efficacy, tolerability, and your clinician's recommendation.
• Self-pay vial path: Zepbound (LillyDirect) has an edge. The LillyDirect starter dose is $349/month (2.5 mg), versus no starter-dose vial option from NovoCare. Therapeutic-dose vials are comparable ($499/month on both programs for their respective maintenance doses). If you're still titrating, LillyDirect is cheaper for the first four weeks.
• Efficacy: SURMOUNT-5, the head-to-head trial of tirzepatide (Zepbound) versus semaglutide (Wegovy) published in 2024, showed tirzepatide delivered approximately 20.2% total body weight loss versus 13.7% for semaglutide at their respective max doses over 72 weeks. Cost per pound lost favors tirzepatide, particularly for patients with significant weight-loss goals.
• Cardiovascular indication: Wegovy holds the SELECT cardiovascular outcomes trial indication — patients with established cardiovascular disease. Zepbound has the SURMOUNT-OSA indication for sleep apnea. For patients choosing on CV-risk grounds, Wegovy's label is more specific to their situation.

Frequently Asked Questions

How much does Wegovy cost without insurance in 2026?

Without any assistance program, Wegovy's 2026 list price is approximately $1,349/month for any dose strength. NovoCare's self-pay vial program brings maintenance-dose cost to $499/month (1.7 mg and 2.4 mg only). The Novo Nordisk savings card applied to a cash-pay retail prescription provides up to $500/month off, landing most patients around $849–$999/month for branded pens. Verify current NovoCare pricing at NovoMedLink.com or your telehealth provider's platform.

Is the Novo Nordisk Wegovy savings card still available in 2026?

Yes, for commercially insured patients whose plans cover Wegovy. The card provides a maximum of $225 off per 28-day supply, with a $3,500 annual benefit cap. For uninsured or non-covered patients, the card offers up to $500/month off the retail cash price. The card is not valid with Medicare, Medicaid, TRICARE, or VA benefits.

What is NovoCare and how does it compare to the savings card?

NovoCare is Novo Nordisk's direct-to-patient vial program launched in late 2025. It prices Wegovy vials at $499/month for 1.7 mg and 2.4 mg maintenance doses, shipped directly to your home. It's a cash-pay program — no insurance billing, no contribution to your deductible. For patients already at maintenance dose without coverage, NovoCare typically beats the savings-card cash-pay path ($499 vs. ~$849). For patients still titrating, NovoCare has no starter-dose vials; you'd need a retail prescription during titration.

Will insurance cover Wegovy if I don't have diabetes?

Possibly, depending on your plan. Commercial plans that cover anti-obesity medications generally require prior authorization with BMI 30+ or BMI 27+ with at least one weight-related comorbidity (hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea, or cardiovascular disease). Approximately 35–45% of large-employer plans covered AOMs as of early 2026. Medicare Part D covers Wegovy only for the SELECT cardiovascular indication. Medicaid coverage varies widely by state — California, Pennsylvania, and Massachusetts have broader AOM coverage; most other states remain restrictive.

Is compounded semaglutide legal in 2026?

The FDA removed semaglutide from the drug shortage list in late 2024. Since then, the broad 503A compounding pathway for general weight loss has legally closed. Compounded semaglutide is still permissible for individual medical necessity with documented justification. Platforms advertising compounded semaglutide broadly without patient-specific indication for compounding are operating outside current FDA guidance. Consult your prescribing clinician and verify your compounding pharmacy's compliance posture.

<iframe src="https://digitaldashboardhub.com/embed-wegovy-cost-calculator-with-without-insurance/" width="100%" height="650" frameborder="0" loading="lazy"></iframe>

More Tools You Might Like

• Calorie Deficit Calculator — Lose Weight Without Obsessing Over Every Bite
• Best Menstrual Cycle Tracker
• PCOS Symptom Tracker & Hormone Dashboard
• Depression Mood Tracker — How Tracking Your Mental Health Data Helps You Heal

Andy Gaber

Andy Gaber is the founder of Digital Dashboard Hub, a suite of 255+ interactive financial, productivity, and wellness tools. He built DDH after getting frustrated with financial apps that gave outputs without context. Follow along for tool tutorials, revenue analytics breakdowns, and honest takes on personal finance.